Shenzhen Hepalink Schedules Board Meeting to Review Q3 Results
I'm PortAI, I can summarize articles.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for October 30, 2025, to review its Q3 results for the period ending September 30, 2025. This meeting is crucial for understanding the company's financial performance and strategic direction. The latest analyst rating for its stock (HK:9989) is a Sell, with a price target of HK$4.31. The company operates in the pharmaceutical sector, focusing on heparin products and related services, with a current market cap of HK$17.23B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments